Clinical review report: Cyclosporine (VERKAZIA) (Santen Canada Inc.) indication : treatment of severe vernal keratoconjunctivitis in children from four years of age through adolescence
The objective of this CADTH Common Drug Review (CDR) report is to perform a systematic review of the beneficial and harmful effects of 0.1% cyclosporine topical ophthalmic emulsion administered as one drop four times a day for the treatment of severe vernal keratoconjunctivitis in children from four...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, January 2020
|
| Edition: | Version: final (with redactions) |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this CADTH Common Drug Review (CDR) report is to perform a systematic review of the beneficial and harmful effects of 0.1% cyclosporine topical ophthalmic emulsion administered as one drop four times a day for the treatment of severe vernal keratoconjunctivitis in children from four years of age through adolescence |
|---|---|
| Physical Description: | 1 PDF file (68 pages) illustrations |